Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothOffering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

            Contact the Supplier

            Lead Product(s): Olopatadine Hydrochloride

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            Dr. Reddy’s has launched of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the storebrand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the USFDA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cetirizine

            Therapeutic Area: Ophthalmology Product Name: Zerviate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nicox SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 05, 2021

            Details:

            Nicox will receive an undisclosed license fee and potential milestone payments linked to regulatory approval and sales, and is eligible to receive double digit royalties on net sales of ZERVIATE.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aflibercept

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alvotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 02, 2021

            Details:

            As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology.